[EATG Global HIV News daily digest] Digest #31-2010

[EATG Global HIV News daily digest]

Global HIV News Daily Digest

Copied as fair use  -  Ana  -



Latest Headlines




  Africa: Continent plans leap into drug research and development
  Access to treatment Friday 19 February 2010
					
  
African ministers, health researchers and pharmaceutical industry
representatives began meeting today to discuss how to boost drug
innovation and production on the continent.
  SOURCE:
allAfrica.com




  Countries urged to review progress made in achieving national AIDS targets
  World Policy Friday 19 February 2010
					
  
Ahead of the UN High-level Meeting on Millennium Development Goals,
UNAIDS calls on all countries to review progress and barriers for
achieving national targets for universal access.
  SOURCE:
UNAIDS




  Rights groups demand protection of gays in Kenya 
  MSM Friday 19 February 2010
					
  
A human rights watchdog says it is alarmed over reports of increasing
vigilante violence in Kenya against people accused of homosexual
conduct and groups offering HIV/AIDS services. 
  SOURCE:
VOANews.com




  'Proof-of-concept' study shows technology stabilizes vaccines at tropical temperatures
  Prevention Friday 19 February 2010
					
  
This could help to revolutionalize vaccination campaigns in developing countries.
  SOURCE:
Kaiser Daily Global Health Policy Report




  OECD reports $21b shortfall in aid pledges by wealthy countries
  World Policy Friday 19 February 2010
					
  
There is a $21 billion shortfall between aid promised in 2005 by some of the world's richest countries and actual payments.
  SOURCE:
Kaiser Daily Global Health Policy Report




  CROI: Study finds few differences in competing drug regimens
  Treatment Friday 19 February 2010
					
  
Four years of clinical data indicate that patients infected with human
immunodeficiency virus and treated with the integrase inhibitor
raltegravir (Isentress) fare as well as patients treated with efavirenz
(Sustiva), researchers here reported. 
  SOURCE:
MedPage Today




  Ireland’s “ridiculous” expensive generics slammed  
  Access to treatment Friday 19 February 2010
					
  
The situation in Ireland whereby some generics are 50% more expensive
than their branded equivalents has been described as “unique in Europe”
and “ridiculous”. 
  SOURCE:
PharmaTimes




  Pharmasset announces complete enrollment of RG7128 Phase 2b clinical study
  Hepatitis Friday 19 February 2010
					
  
Roche initiating additional clinical studies with RG7128 - INFORM studies delayed.
  SOURCE:
Pharmasset, Inc.




  Study demonstrates once-a-week TB drug is as effective as daily dose
  Tuberculosis & Malaria Friday 19 February 2010
					
  
Researchers are one step closer to providing tuberculosis sufferers
with a once-a-week medicinal regime rather than their current daily
doses. 
  SOURCE:
The Medical News




  CROI: Contraception affirmed safe in HIV
  Treatment Thursday 18 February 2010
					
  
Hormonal contraception carries no harm for women with HIV, according to observational findings that may help allay concerns.
  SOURCE:
MedPage Today




  CROI: Couples strategy cuts HIV transmission
  Prevention Thursday 18 February 2010
					
  
Antiretroviral treatment is highly effective at reducing risk of HIV
transmission to uninfected partners, prospective data has affirmed.
  SOURCE:
MedPage Today




  H1N1 meets HIV
  Treatment Thursday 18 February 2010
					
  
People with HIV are generally no more likely to experience severe
complications of H1N1 influenza virus than people not infected with HIV.
  SOURCE:
AIDSmeds.com




  PEG-IFN/ribavirin: More adverse effects, worse adherence in older HCV-1 patients
  Hepatitis Thursday 18 February 2010
					
  
Older patients with chronic hepatitis C virus infection -- especially
those with HCV genotype 1 -- have poorer response to treatment, more
adverse events, and poorer adherence.
  SOURCE:
Medscape Today




  ACTG
5202: No significant difference in time to failure between Kivexa and
Truvada in patients with lower viral loads when paired with efavirenz
or atazanavir 
  Treatment Thursday 18 February 2010
					
  
Unlike prior results in patients with viral loads higher than 100,000
copies/ml, in which virologic failure occurred more quickly with
abacavir/3TC than with tenofovir/emtricitabine, there was no
significant difference in outcomes between these two nucleoside
backbones in patients with viral loads under 100,000 copies/ml. 
  SOURCE:
Aidsmap




  Overall HIV prevalence stabilises at 11% in South Africa, with decreases in younger age groups 
  Epidemiology Thursday 18 February 2010
					
  
Results of three national HIV household surveys spanning six years
indicate that HIV prevalence has stabilised at 11% in South Africa,
with signs that the rate of infection is falling in younger age groups.

  SOURCE:
Aidsmap




  Increased testing leads to decrease in viral load and infections in San Francisco, and in late diagnosis in Washington 
  Prevention Thursday 18 February 2010
					
  
The HIV infection rate in San Francisco appears to be falling, and the
fall is associated with a reduction in the average viral load in
HIV-positive people, due to more people on treatment.
  SOURCE:
Aidsmap




  French gay men face sixtyfold HIV risk: incidence increasing in Netherlands 
  MSM Thursday 18 February 2010
					
  
Two studies from Europe have found that HIV incidence is not decreasing in gay men, and in some populations may be increasing. 
  SOURCE:
Aidsmap




  Once-daily darunavir effective and less toxic than twice-daily in experienced patients without prior darunavir resistance: ODIN 
  Treatment Thursday 18 February 2010
					
  
A once-daily dose of 800mg darunavir was as effective at suppressing
viral load as a 600mg twice-daily dose in treatment-experienced
patients who did not have resistance mutations to darunavir at the
start of the trial. The once-daily dose was also less likely to cause
lipid disturbances. 
  SOURCE:
Aidsmap




  CCR5 antagonist vicriviroc fails to surpass potent background regimen 
  Treatment Thursday 18 February 2010
					
  
Based on these results, developer Merck has indicated that it will not
submit a New Drug Application to the US Food and Drug Administration
for vicriviroc for treatment-experienced individuals.
  SOURCE:
Aidsmap




  New CCR5 antagonist TBR-652 shows good antiviral activity in early study 
  Treatment Thursday 18 February 2010
					
  
Based on the favourable findings from this proof-of-concept trial, Tobira is moving forward with Phase 2b studies of the drug. 
  SOURCE:
Aidsmap




  Elvitegravir 'Quad' pill performs well, new booster cobicistat works as well as ritonavir 
  Treatment Thursday 18 February 2010
					
  
Based on the favourable results from these studies, Gilead Sciences
expects to move into Phase 3 trials of cobicistat and the Quad pill
later this year. 
  SOURCE:
Aidsmap




  Risk factors for lung cancer in people with HIV: smoking vastly outweighs HIV 
  Treatment Thursday 18 February 2010
					
  
Smoking vastly outweighs HIV infection as a risk factor for lung cancer
in people with HIV, a large study of US veterans has revealed. 
  SOURCE:
Aidsmap


----------------------------------------------------
DISCLAIMER
The articles in this digest represent a diversity of opinions on topics
of interest to the HIV treatment activist community. The EATG is not
responsible for their content. The articles posted in this digest do
not necessarily reflect EATG views or opinions.
FAIR USE NOTICE
The digest may contain copyrighted material which has not always been
specifically authorised by the copyright owner. Such material is made
available for educational purposes to advance the understanding of
scientific, ethical, legal and social issues. It is believed that this
constitutes a 'fair use' of any such copyrighted material. This
material is distributed without profit.


 

Information in this digest was accurately quoted during its compilation.




      
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://mail.eatg.org/pipermail/eatg-forum_eatg.org/attachments/20100218/b4683345/attachment-0001.html>